



REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | SECOND QUARTER | | | | | SIX MONTHS | | | | |
|--|----------------|----------|----------|----------------------------|----------|------------|----------|----------|----------------------------|----------|
| | 2018 | 2017 | % Change | | | 2018 | 2017 | % Change | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency |
| CONSUMER SEGMENT ⁽²⁾ | | | | | | | | | | |
| BABY CARE | | | | | | | | | | |
| US | \$ 89 | \$ 113 | -21.2% | -21.2% | - | \$ 186 | \$ 226 | -17.7% | -17.7% | - |
| Intl | 367 | 381 | -3.7% | -2.7% | -1.0% | 727 | 723 | 0.6% | -0.8% | 1.4% |
| WW | 456 | 494 | -7.7% | -6.9% | -0.8% | 913 | 949 | -3.8% | -4.8% | 1.0% |
| BEAUTY | | | | | | | | | | |
| US | 637 | 649 | -1.8% | -1.8% | - | 1,248 | 1,216 | 2.6% | 2.6% | - |
| Intl | 472 | 427 | 10.5% | 7.3% | 3.2% | 945 | 841 | 12.4% | 6.8% | 5.6% |
| WW | 1,109 | 1,076 | 3.1% | 1.8% | 1.3% | 2,193 | 2,057 | 6.6% | 4.3% | 2.3% |
| ORAL CARE | | | | | | | | | | |
| US | 157 | 150 | 4.7% | 4.7% | - | 314 | 306 | 2.6% | 2.6% | - |
| Intl | 236 | 244 | -3.3% | -5.5% | 2.2% | 458 | 450 | 1.8% | -2.7% | 4.5% |
| WW | 393 | 394 | -0.3% | -1.7% | 1.4% | 772 | 756 | 2.1% | -0.6% | 2.7% |
| OTC | | | | | | | | | | |
| US | 454 | 432 | 5.1% | 5.1% | - | 919 | 909 | 1.1% | 1.1% | - |
| Intl | 612 | 574 | 6.6% | 2.5% | 4.1% | 1,219 | 1,110 | 9.8% | 3.2% | 6.6% |
| WW | 1,066 | 1,006 | 6.0% | 3.7% | 2.3% | 2,138 | 2,019 | 5.9% | 2.2% | 3.7% |
| WOMEN'S HEALTH | | | | | | | | | | |
| US | 4 | 3 | 33.3% | 33.3% | - | 7 | 6 | 16.7% | 16.7% | - |
| Intl | 276 | 273 | 1.1% | 1.9% | -0.8% | 516 | 512 | 0.8% | -1.1% | 1.9% |
| WW | 280 | 276 | 1.4% | 2.2% | -0.8% | 523 | 518 | 1.0% | -0.9% | 1.9% |
| WOUND CARE / OTHER | | | | | | | | | | |
| US | 135 | 140 | -3.6% | -3.6% | - | 238 | 238 | 0.0% | 0.0% | - |
| Intl | 65 | 92 | -29.3% | -31.3% | 2.0% | 125 | 169 | -26.0% | -29.2% | 3.2% |
| WW | 200 | 232 | -13.8% | -14.6% | 0.8% | 363 | 407 | -10.8% | -12.1% | 1.3% |
| TOTAL CONSUMER | | | | | | | | | | |
| US | 1,476 | 1,487 | -0.7% | -0.7% | - | 2,912 | 2,901 | 0.4% | 0.4% | - |
| Intl | 2,028 | 1,991 | 1.9% | 0.0% | 1.9% | 3,990 | 3,805 | 4.9% | 0.5% | 4.4% |
| WW | \$ 3,504 | \$ 3,478 | 0.7% | -0.4% | 1.1% | \$ 6,902 | \$ 6,706 | 2.9% | 0.4% | 2.5% |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | SECOND QUARTER | | | | | SIX MONTHS | | | | |
|--|----------------|----------|----------|----------------------------|----------|------------|----------|----------|----------------------------|----------|
| | 2018 | 2017 | % Change | | | 2018 | 2017 | % Change | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency |
| PHARMACEUTICAL SEGMENT ⁽²⁾⁽⁵⁾ | | | | | | | | | | |
| IMMUNOLOGY | | | | | | | | | | |
| US | \$ 2,317 | \$ 2,101 | 10.3% | 10.3% | - | \$ 4,317 | \$ 4,224 | 2.2% | 2.2% | - |
| Intl | 1,021 | 858 | 19.0% | 14.6% | 4.4% | 2,063 | 1,665 | 23.9% | 17.0% | 6.9% |
| WW | 3,338 | 2,959 | 12.8% | 11.5% | 1.3% | 6,380 | 5,889 | 8.3% | 6.3% | 2.0% |
| REMICADE | | | | | | | | | | |
| US | 918 | 1,064 | -13.7% | -13.7% | - | 1,834 | 2,246 | -18.3% | -18.3% | - |
| US Exports ⁽³⁾ | 104 | 127 | -18.1% | -18.1% | - | 246 | 292 | -15.8% | -15.8% | - |
| Intl | 298 | 339 | -12.1% | -14.0% | 1.9% | 629 | 664 | -5.3% | -9.0% | 3.7% |
| WW | 1,320 | 1,530 | -13.7% | -14.1% | 0.4% | 2,709 | 3,202 | -15.4% | -16.2% | 0.8% |
| SIMPONI / SIMPONI ARIA | | | | | | | | | | |
| US | 274 | 230 | 19.1% | 19.1% | - | 498 | 459 | 8.5% | 8.5% | - |
| Intl | 274 | 209 | 31.1% | 26.9% | 4.2% | 568 | 408 | 39.2% | 32.0% | 7.2% |
| WW | 548 | 439 | 24.8% | 22.8% | 2.0% | 1,066 | 867 | 23.0% | 19.6% | 3.4% |
| STELARA | | | | | | | | | | |
| US | 919 | 680 | 35.1% | 35.1% | - | 1,571 | 1,227 | 28.0% | 28.0% | - |
| Intl | 422 | 303 | 39.3% | 32.0% | 7.3% | 831 | 579 | 43.5% | 32.9% | 10.6% |
| WW | 1,341 | 983 | 36.4% | 34.2% | 2.2% | 2,402 | 1,806 | 33.0% | 29.6% | 3.4% |
| OTHER IMMUNOLOGY | | | | | | | | | | |
| US | 102 | - | * | * | - | 168 | - | * | * | - |
| Intl | 27 | 7 | * | * | * | 35 | 14 | * | * | * |
| WW | 129 | 7 | * | * | * | 203 | 14 | * | * | * |
| INFECTIOUS DISEASES | | | | | | | | | | |
| US | 328 | 341 | -3.8% | -3.8% | - | 661 | 667 | -0.9% | -0.9% | - |
| Intl | 521 | 451 | 15.5% | 11.0% | 4.5% | 1,018 | 874 | 16.5% | 8.5% | 8.0% |
| WW | 849 | 792 | 7.2% | 4.6% | 2.6% | 1,679 | 1,541 | 9.0% | 4.5% | 4.5% |
| EDURANT / rilpivirine | | | | | | | | | | |
| US | 15 | 17 | -11.8% | -11.8% | - | 29 | 29 | 0.0% | 0.0% | - |
| Intl | 196 | 162 | 21.0% | 13.1% | 7.9% | 392 | 299 | 31.1% | 18.6% | 12.5% |
| WW | 211 | 179 | 17.9% | 10.7% | 7.2% | 421 | 328 | 28.4% | 17.0% | 11.4% |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | | | | | | |
| US | 277 | 278 | -0.4% | -0.4% | - | 550 | 537 | 2.4% | 2.4% | - |
| Intl | 215 | 176 | 22.2% | 18.8% | 3.4% | 420 | 347 | 21.0% | 14.1% | 6.9% |
| WW | 492 | 454 | 8.4% | 7.1% | 1.3% | 970 | 884 | 9.7% | 7.0% | 2.7% |
| OTHER INFECTIOUS DISEASES | | | | | | | | | | |
| US | 36 | 46 | -21.7% | -21.7% | - | 82 | 101 | -18.8% | -18.8% | - |
| Intl | 110 | 113 | -2.7% | -4.1% | 1.4% | 206 | 228 | -9.6% | -13.3% | 3.7% |
| WW | 146 | 159 | -8.2% | -9.2% | 1.0% | 288 | 329 | -12.5% | -15.1% | 2.6% |

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | SECOND QUARTER | | | | | SIX MONTHS | | | | | |
|--|----------------|-------|----------|----------------------------|----------|------------|-------|----------|----------------------------|----------|--|
| | 2018 | 2017 | % Change | | | 2018 | 2017 | % Change | | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency | |
| NEUROSCIENCE | | | | | | | | | | | |
| US | 639 | 620 | 3.1% | 3.1% | - | 1,263 | 1,284 | -1.6% | -1.6% | - | |
| Intl | 889 | 847 | 5.0% | 1.4% | 3.6% | 1,824 | 1,680 | 8.6% | 2.4% | 6.2% | |
| WW | 1,528 | 1,467 | 4.2% | 2.1% | 2.1% | 3,087 | 2,964 | 4.1% | 0.6% | 3.5% | |
| <u>CONCERTA / methylphenidate</u> | | | | | | | | | | | |
| US | 68 | 76 | -10.5% | -10.5% | - | 134 | 184 | -27.2% | -27.2% | - | |
| Intl | 115 | 105 | 9.5% | 6.9% | 2.6% | 222 | 206 | 7.8% | 3.1% | 4.7% | |
| WW | 183 | 181 | 1.1% | -0.4% | 1.5% | 356 | 390 | -8.7% | -11.2% | 2.5% | |
| <u>INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA</u> | | | | | | | | | | | |
| US | 438 | 387 | 13.2% | 13.2% | - | 838 | 759 | 10.4% | 10.4% | - | |
| Intl | 282 | 242 | 16.5% | 10.5% | 6.0% | 578 | 474 | 21.9% | 12.8% | 9.1% | |
| WW | 720 | 629 | 14.5% | 12.2% | 2.3% | 1,416 | 1,233 | 14.8% | 11.3% | 3.5% | |
| <u>RISPERDAL CONSTA</u> | | | | | | | | | | | |
| US | 80 | 91 | -12.1% | -12.1% | - | 162 | 186 | -12.9% | -12.9% | - | |
| Intl | 108 | 116 | -6.9% | -10.3% | 3.4% | 222 | 228 | -2.6% | -8.7% | 6.1% | |
| WW | 188 | 207 | -9.2% | -11.1% | 1.9% | 384 | 414 | -7.2% | -10.6% | 3.4% | |
| <u>OTHER NEUROSCIENCE</u> | | | | | | | | | | | |
| US | 53 | 66 | -19.7% | -19.7% | - | 129 | 155 | -16.8% | -16.8% | - | |
| Intl | 384 | 384 | 0.0% | -2.4% | 2.4% | 802 | 772 | 3.9% | -1.0% | 4.9% | |
| WW | 437 | 450 | -2.9% | -5.0% | 2.1% | 931 | 927 | 0.4% | -3.6% | 4.0% | |
| ONCOLOGY | | | | | | | | | | | |
| US | 1,085 | 697 | 55.7% | 55.7% | - | 2,018 | 1,361 | 48.3% | 48.3% | - | |
| Intl | 1,371 | 1,030 | 33.1% | 27.2% | 5.9% | 2,749 | 1,960 | 40.3% | 30.7% | 9.6% | |
| WW | 2,456 | 1,727 | 42.2% | 38.7% | 3.5% | 4,767 | 3,321 | 43.5% | 37.8% | 5.7% | |
| <u>DARZALEX</u> | | | | | | | | | | | |
| US | 298 | 212 | 40.6% | 40.6% | - | 562 | 413 | 36.1% | 36.1% | - | |
| Intl | 213 | 87 | * | * | * | 381 | 141 | * | * | * | |
| WW | 511 | 299 | 70.9% | 67.7% | 3.2% | 943 | 554 | 70.2% | 65.8% | 4.4% | |
| <u>IMBRUVICA</u> | | | | | | | | | | | |
| US | 250 | 202 | 23.8% | 23.8% | - | 477 | 392 | 21.7% | 21.7% | - | |
| Intl | 370 | 248 | 49.2% | 42.7% | 6.5% | 730 | 467 | 56.3% | 45.7% | 10.6% | |
| WW | 620 | 450 | 37.8% | 34.2% | 3.6% | 1,207 | 859 | 40.5% | 34.7% | 5.8% | |
| <u>VELCADE</u> | | | | | | | | | | | |
| US | - | - | - | - | - | - | - | - | - | - | |
| Intl | 280 | 290 | -3.4% | -8.0% | 4.6% | 593 | 570 | 4.0% | -3.4% | 7.4% | |
| WW | 280 | 290 | -3.4% | -8.0% | 4.6% | 593 | 570 | 4.0% | -3.4% | 7.4% | |
| <u>ZYTIGA</u> | | | | | | | | | | | |
| US | 486 | 241 | * | * | - | 893 | 474 | 88.4% | 88.4% | - | |
| Intl | 423 | 317 | 33.4% | 27.3% | 6.1% | 861 | 607 | 41.8% | 31.8% | 10.0% | |
| WW | 909 | 558 | 62.9% | 59.5% | 3.4% | 1,754 | 1,081 | 62.3% | 56.7% | 5.6% | |
| <u>OTHER ONCOLOGY</u> | | | | | | | | | | | |
| US | 51 | 42 | 21.4% | 21.4% | - | 86 | 82 | 4.9% | 4.9% | - | |
| Intl | 85 | 88 | -3.4% | -6.8% | 3.4% | 184 | 175 | 5.1% | -1.5% | 6.6% | |
| WW | 136 | 130 | 4.6% | 2.3% | 2.3% | 270 | 257 | 5.1% | 0.6% | 4.5% | |

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | SECOND QUARTER | | | | | SIX MONTHS | | | | |
|---|----------------|----------|----------|----------------------------|----------|------------|-----------|----------|----------------------------|----------|
| | 2018 | 2017 | % Change | | | 2018 | 2017 | % Change | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency |
| PULMONARY HYPERTENSION⁽⁴⁾ | | | | | | | | | | |
| US | 429 | 37 | * | * | - | 790 | 37 | * | * | - |
| Intl | 236 | 48 | * | * | * | 460 | 48 | * | * | * |
| WW | 665 | 85 | * | * | * | 1,250 | 85 | * | * | * |
| <u>OPSUMIT</u> | | | | | | | | | | |
| US | 180 | 24 | * | * | - | 329 | 24 | * | * | - |
| Intl | 131 | 21 | * | * | * | 253 | 21 | * | * | * |
| WW | 311 | 45 | * | * | * | 582 | 45 | * | * | * |
| <u>TRACLEER</u> | | | | | | | | | | |
| US | 71 | 2 | * | * | - | 139 | 2 | * | * | - |
| Intl | 72 | 24 | * | * | * | 144 | 24 | * | * | * |
| WW | 143 | 26 | * | * | * | 283 | 26 | * | * | * |
| <u>UPTRAVI</u> | | | | | | | | | | |
| US | 155 | 8 | * | * | - | 279 | 8 | * | * | - |
| Intl | 16 | 1 | * | * | * | 32 | 1 | * | * | * |
| WW | 171 | 9 | * | * | * | 311 | 9 | * | * | * |
| <u>OTHER</u> | | | | | | | | | | |
| US | 23 | 3 | * | * | - | 43 | 3 | * | * | - |
| Intl | 17 | 2 | * | * | * | 31 | 2 | * | * | * |
| WW | 40 | 5 | * | * | * | 74 | 5 | * | * | * |
| CARDIOVASCULAR / METABOLISM / OTHER | | | | | | | | | | |
| US | 1,101 | 1,214 | -9.3% | -9.3% | - | 2,204 | 2,309 | -4.5% | -4.5% | - |
| Intl | 417 | 391 | 6.6% | 1.9% | 4.7% | 831 | 771 | 7.8% | 1.7% | 6.1% |
| WW | 1,518 | 1,605 | -5.4% | -6.6% | 1.2% | 3,035 | 3,080 | -1.5% | -3.0% | 1.5% |
| <u>XARELTO</u> | | | | | | | | | | |
| US | 679 | 642 | 5.8% | 5.8% | - | 1,257 | 1,155 | 8.8% | 8.8% | - |
| Intl | - | - | - | - | - | - | - | - | - | - |
| WW | 679 | 642 | 5.8% | 5.8% | - | 1,257 | 1,155 | 8.8% | 8.8% | - |
| <u>INVOKANA / INVOKAMET</u> | | | | | | | | | | |
| US | 169 | 256 | -34.0% | -34.0% | - | 373 | 503 | -25.8% | -25.8% | - |
| Intl | 46 | 39 | 17.9% | 13.0% | 4.9% | 90 | 76 | 18.4% | 11.7% | 6.7% |
| WW | 215 | 295 | -27.1% | -27.7% | 0.6% | 463 | 579 | -20.0% | -20.9% | 0.9% |
| <u>PROCIT / EPREX</u> | | | | | | | | | | |
| US | 156 | 174 | -10.3% | -10.3% | - | 345 | 343 | 0.6% | 0.6% | - |
| Intl | 80 | 81 | -1.2% | -5.9% | 4.7% | 167 | 159 | 5.0% | -1.7% | 6.7% |
| WW | 236 | 255 | -7.5% | -9.0% | 1.5% | 512 | 502 | 2.0% | -0.1% | 2.1% |
| <u>OTHER</u> | | | | | | | | | | |
| US | 97 | 142 | -31.7% | -31.7% | - | 229 | 308 | -25.6% | -25.6% | - |
| Intl | 291 | 271 | 7.4% | 2.7% | 4.7% | 574 | 536 | 7.1% | 1.3% | 5.8% |
| WW | 388 | 413 | -6.1% | -9.2% | 3.1% | 803 | 844 | -4.9% | -8.6% | 3.7% |
| TOTAL PHARMACEUTICAL | | | | | | | | | | |
| US | 5,899 | 5,010 | 17.7% | 17.7% | - | 11,253 | 9,882 | 13.9% | 13.9% | - |
| Intl | 4,455 | 3,625 | 22.9% | 17.5% | 5.4% | 8,945 | 6,998 | 27.8% | 19.9% | 7.9% |
| WW | \$ 10,354 | \$ 8,635 | 19.9% | 17.6% | 2.3% | \$ 20,198 | \$ 16,880 | 19.7% | 16.4% | 3.3% |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | SECOND QUARTER | | | | | SIX MONTHS | | | | | | |
|--|----------------|----------|----------|----------------------------|----------|------------|-----------|----------|----------------------------|----------|--|--|
| | 2018 | 2017 | % Change | | | 2018 | 2017 | % Change | | | | |
| | | | Reported | Operational ⁽¹⁾ | Currency | | | Reported | Operational ⁽¹⁾ | Currency | | |
| MEDICAL DEVICES SEGMENT ⁽²⁾⁽⁵⁾ | | | | | | | | | | | | |
| DIABETES CARE | | | | | | | | | | | | |
| US | \$ 129 | \$ 160 | -19.4% | -19.4% | - | \$ 246 | \$ 314 | -21.7% | -21.7% | - | | |
| Intl | 226 | 261 | -13.4% | -16.3% | 2.9% | 448 | 506 | -11.5% | -16.6% | 5.1% | | |
| WW | 355 | 421 | -15.7% | -17.5% | 1.8% | 694 | 820 | -15.4% | -18.5% | 3.1% | | |
| DIAGNOSTICS | | | | | | | | | | | | |
| US | - | - | - | - | - | - | - | - | - | - | | |
| Intl | - | - | - | - | - | - | 1 | * | * | * | | |
| WW | - | - | - | - | - | - | 1 | * | * | * | | |
| INTERVENTIONAL SOLUTIONS | | | | | | | | | | | | |
| US | 323 | 285 | 13.3% | 13.3% | 0.0% | 627 | 564 | 11.2% | 11.2% | - | | |
| Intl | 344 | 288 | 19.4% | 14.1% | 5.3% | 680 | 558 | 21.9% | 14.2% | 7.7% | | |
| WW | 667 | 573 | 16.4% | 13.7% | 2.7% | 1,307 | 1,122 | 16.5% | 12.7% | 3.8% | | |
| ORTHOPAEDICS | | | | | | | | | | | | |
| US | 1,332 | 1,367 | -2.6% | -2.6% | - | 2,639 | 2,726 | -3.2% | -3.2% | - | | |
| Intl | 930 | 926 | 0.4% | -3.6% | 4.0% | 1,873 | 1,842 | 1.7% | -4.6% | 6.3% | | |
| WW | 2,262 | 2,293 | -1.4% | -3.0% | 1.6% | 4,512 | 4,568 | -1.2% | -3.8% | 2.6% | | |
| HIPS | | | | | | | | | | | | |
| US | 211 | 208 | 1.4% | 1.4% | - | 420 | 417 | 0.7% | 0.7% | - | | |
| Intl | 149 | 142 | 4.9% | 0.8% | 4.1% | 303 | 285 | 6.3% | -0.2% | 6.5% | | |
| WW | 360 | 350 | 2.9% | 1.2% | 1.7% | 723 | 702 | 3.0% | 0.3% | 2.7% | | |
| KNEES | | | | | | | | | | | | |
| US | 229 | 236 | -3.0% | -3.0% | - | 457 | 482 | -5.2% | -5.2% | - | | |
| Intl | 153 | 149 | 2.7% | -0.8% | 3.5% | 312 | 301 | 3.7% | -2.5% | 6.2% | | |
| WW | 382 | 385 | -0.8% | -2.2% | 1.4% | 769 | 783 | -1.8% | -4.2% | 2.4% | | |
| TRAUMA | | | | | | | | | | | | |
| US | 394 | 390 | 1.0% | 1.0% | - | 801 | 781 | 2.6% | 2.6% | - | | |
| Intl | 281 | 253 | 11.1% | 6.7% | 4.4% | 570 | 504 | 13.1% | 6.2% | 6.9% | | |
| WW | 675 | 643 | 5.0% | 3.3% | 1.7% | 1,371 | 1,285 | 6.7% | 4.0% | 2.7% | | |
| SPINE & OTHER | | | | | | | | | | | | |
| US | 498 | 533 | -6.6% | -6.6% | - | 961 | 1,046 | -8.1% | -8.1% | - | | |
| Intl | 347 | 382 | -9.2% | -13.2% | 4.0% | 688 | 752 | -8.5% | -14.5% | 6.0% | | |
| WW | 845 | 915 | -7.7% | -9.4% | 1.7% | 1,649 | 1,798 | -8.3% | -10.8% | 2.5% | | |
| SURGERY | | | | | | | | | | | | |
| US | 1,022 | 1,012 | 1.0% | 1.0% | - | 2,015 | 2,007 | 0.4% | 0.4% | - | | |
| Intl | 1,493 | 1,372 | 8.8% | 5.4% | 3.4% | 2,923 | 2,648 | 10.4% | 4.7% | 5.7% | | |
| WW | 2,515 | 2,384 | 5.5% | 3.5% | 2.0% | 4,938 | 4,655 | 6.1% | 2.9% | 3.2% | | |
| ADVANCED | | | | | | | | | | | | |
| US | 402 | 400 | 0.5% | 0.5% | - | 795 | 792 | 0.4% | 0.4% | - | | |
| Intl | 603 | 533 | 13.1% | 9.1% | 4.0% | 1,176 | 1,018 | 15.5% | 9.3% | 6.2% | | |
| WW | 1,005 | 933 | 7.7% | 5.4% | 2.3% | 1,971 | 1,810 | 8.9% | 5.4% | 3.5% | | |
| GENERAL | | | | | | | | | | | | |
| US | 436 | 423 | 3.1% | 3.1% | - | 859 | 846 | 1.5% | 1.5% | - | | |
| Intl | 733 | 691 | 6.1% | 2.9% | 3.2% | 1,437 | 1,342 | 7.1% | 1.5% | 5.6% | | |
| WW | 1,169 | 1,114 | 4.9% | 2.9% | 2.0% | 2,296 | 2,188 | 4.9% | 1.5% | 3.4% | | |
| SPECIALTY | | | | | | | | | | | | |
| US | 184 | 189 | -2.6% | -2.6% | - | 361 | 369 | -2.2% | -2.2% | - | | |
| Intl | 157 | 148 | 6.1% | 4.2% | 1.9% | 310 | 288 | 7.6% | 3.4% | 4.2% | | |
| WW | 341 | 337 | 1.2% | 0.4% | 0.8% | 671 | 657 | 2.1% | 0.3% | 1.8% | | |
| VISION | | | | | | | | | | | | |
| US | 459 | 405 | 13.3% | 13.3% | - | 899 | 710 | 26.6% | 26.6% | - | | |
| Intl | 714 | 650 | 9.8% | 7.2% | 2.6% | 1,389 | 1,143 | 21.5% | 16.3% | 5.2% | | |
| WW | 1,173 | 1,055 | 11.2% | 9.6% | 1.6% | 2,288 | 1,853 | 23.5% | 20.3% | 3.2% | | |
| CONTACT LENSES / OTHER | | | | | | | | | | | | |
| US | 320 | 274 | 16.8% | 16.8% | - | 629 | 530 | 18.7% | 18.7% | - | | |
| Intl | 524 | 479 | 9.4% | 6.8% | 2.6% | 1,022 | 906 | 12.8% | 8.0% | 4.8% | | |
| WW | 844 | 753 | 12.1% | 10.4% | 1.7% | 1,651 | 1,436 | 15.0% | 12.0% | 3.0% | | |
| SURGICAL | | | | | | | | | | | | |
| US | 139 | 131 | 6.1% | 6.1% | - | 270 | 180 | 50.0% | 50.0% | - | | |
| Intl | 190 | 171 | 11.1% | 8.6% | 2.5% | 367 | 237 | 54.9% | 48.3% | 6.6% | | |
| WW | 329 | 302 | 8.9% | 7.5% | 1.4% | 637 | 417 | 52.8% | 49.1% | 3.7% | | |
| TOTAL MEDICAL DEVICES | | | | | | | | | | | | |
| US | 3,265 | 3,229 | 1.1% | 1.1% | - | 6,426 | 6,321 | 1.7% | 1.7% | - | | |
| Intl | 3,707 | 3,497 | 6.0% | 2.5% | 3.5% | 7,313 | 6,698 | 9.2% | 3.3% | 5.9% | | |
| WW | \$ 6,972 | \$ 6,726 | 3.7% | 1.9% | 1.8% | \$ 13,739 | \$ 13,019 | 5.5% | 2.5% | 3.0% | | |

* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Products acquired from Actelion acquisition on June 16, 2017
(5) Prior year amounts have been reclassified to conform to current year product disclosure